NZ719045B2 - Systems and methods of treatment using intervention and tasking determination - Google Patents
Systems and methods of treatment using intervention and tasking determination Download PDFInfo
- Publication number
- NZ719045B2 NZ719045B2 NZ719045A NZ71904514A NZ719045B2 NZ 719045 B2 NZ719045 B2 NZ 719045B2 NZ 719045 A NZ719045 A NZ 719045A NZ 71904514 A NZ71904514 A NZ 71904514A NZ 719045 B2 NZ719045 B2 NZ 719045B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- patient
- information
- intervention
- fields
- physician
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 133
- 238000000034 method Methods 0.000 title abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 90
- 229940079593 drug Drugs 0.000 claims abstract description 86
- 238000004422 calculation algorithm Methods 0.000 claims description 36
- 230000004044 response Effects 0.000 claims description 17
- 238000012545 processing Methods 0.000 claims description 16
- 229960003248 mifepristone Drugs 0.000 claims description 11
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 claims description 11
- 230000008859 change Effects 0.000 claims description 5
- 208000014311 Cushing syndrome Diseases 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 238000012790 confirmation Methods 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 2
- 230000000007 visual effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 11
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 238000004458 analytical method Methods 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- 230000003993 interaction Effects 0.000 description 15
- 238000004891 communication Methods 0.000 description 13
- 230000036541 health Effects 0.000 description 12
- 230000002411 adverse Effects 0.000 description 10
- 230000036470 plasma concentration Effects 0.000 description 10
- 230000008569 process Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000004448 titration Methods 0.000 description 7
- 238000012384 transportation and delivery Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 5
- 238000013439 planning Methods 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 238000011369 optimal treatment Methods 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 3
- 241000282465 Canis Species 0.000 description 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 208000000819 Adrenocortical Hyperfunction Diseases 0.000 description 1
- 208000031872 Body Remains Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 206010020564 Hyperadrenocorticism Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000003635 glucocorticoid antagonist Substances 0.000 description 1
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 239000002394 mineralocorticoid antagonist Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000003237 recreational drug Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4833—Assessment of subject's compliance to treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/7405—Details of notification to user or communication with user or patient ; user input means using sound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/742—Details of notification to user or communication with user or patient ; user input means using visual displays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/746—Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/7465—Arrangements for interactive communication between patient and care services, e.g. by using a telephone network
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
- G06Q10/10—Office automation; Time management
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/20—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
Abstract
Devices, systems, and methods for use in managing patient treatments utilizing pharmaceutical or therapeutic compounds. Methods include accessing one or more fields of information relating to any of a patient, physician and drug treatment and relating the one or more fields, or combination thereof, to a particular attribute or outcome. By analyzing the one or more fields of data in relation to the attribute or outcome, the system determines suitability of an intervention(s) and tasks the intervention(s) to one or more entities to facilitate the desired attribute or outcome. In certain aspects, the system facilitates identification of complex relationships and trends between seemingly unrelated fields of information and outputs information for use in an intervention or various other purposes according to the attribute or outcome desired by the user. to a particular attribute or outcome. By analyzing the one or more fields of data in relation to the attribute or outcome, the system determines suitability of an intervention(s) and tasks the intervention(s) to one or more entities to facilitate the desired attribute or outcome. In certain aspects, the system facilitates identification of complex relationships and trends between seemingly unrelated fields of information and outputs information for use in an intervention or various other purposes according to the attribute or outcome desired by the user.
Description
SYSTEMS AND S OF TREATMENT USING ENTION AND G DETERMINATION CROSS-REFERENCES TO RELATED APPLICATIONS id="p-1" id="p-1" id="p-1" id="p-1" id="p-1" id="p-1" id="p-1" id="p-1"
id="p-1"
[0001] This application claims the benefit of priority to US. Provisional Application No. 61/880,785, filed on September 20, 2013, the entire contents of which are incorporated herein by reference.
BACKGROUND OF THE INVENTION The t invention generally ns to treatments utilizing administration of pharmaceutical or other therapeutic compounds.
While medical treatments utilizing stration of pharmaceutical or therapeutics are widespread, the effectiveness of a given treatment may vary widely from patient to patient. Even when the efficacy of a given treatment has a high degree of predictability in most patients, the success of treatment may still vary considerably based on the patient’s compliance with the prescribed treatment as well as the ability of the physician to prescribe an appropriate treatment regimen for a given patient. These difficulties can become even more problematic when the effect of a treatment and associated pharmaceutical or therapeutic is less predictable, varying considerably between patients.
Given the complexities and challenges posed by conventional approaches to treatments utilizing administration of pharmaceuticals, there exists a need for methods of treatment that provide ed patient outcomes and t compliance. There r exists a need to provide improved management and administration of such treatments.
BRIEF SUMMARY OF THE INVENTION id="p-5" id="p-5" id="p-5" id="p-5" id="p-5" id="p-5" id="p-5" id="p-5"
id="p-5"
[0005] The present invention generally pertains to treatments utilizing administration of pharmaceutical or other therapeutic compounds. In particular, the invention pertains to methods of ng such treatments by identifying suitability of interventions and tasking an individual or entity with the intervention to improve patient compliance, treatment outcomes or other d result.
BRIEF DESCRIPTION OF THE DRAWINGS illustrates a graphical system overview of example ment of the invention. illustrates an information flow diagram in an example embodiment, in accordance with methods of the invention. illustrates an ation flow diagram of data manipulation in an embodiment, in ance with methods of the invention. illustrates an example relationship determined in an example embodiment, in accordance with methods of the invention. id="p-10" id="p-10" id="p-10" id="p-10" id="p-10" id="p-10" id="p-10" id="p-10"
id="p-10"
[0010] illustrates an example relationship determined in an example embodiment.
FIGS. 6A illustrate an example user interface y in an embodiment of the system.
FIGS. 6B-6C illustrate example user reports provided by a system of an embodiment. id="p-13" id="p-13" id="p-13" id="p-13" id="p-13" id="p-13" id="p-13" id="p-13"
id="p-13"
[0013] FIGS. 7-11 illustrate example methods in accordance with embodiments of the invention.
DETAILED DESCRIPTION OF THE INVENTION The present invention lly provides methods and systems for use in t ents, particularly in patient treatments utilizing one or more drugs or therapeutic compounds. In n aspects, the system provides methods of treatment that utilize a relational database or information system that accesses fields of information relating to a patient, physician, or treatment are and analyzes the fields of information to determine and/or identify relationships between one or more fields and a desired attribute or result. The desired attribute or result may include any of: ed patient compliance or treatment outcomes, physician compliance, adherence to a treatment regimen or associated updates or modification to a regimen or associated follow-up. Using the relationship, the system may identify a need for an ention and task the intervention to one or more entities to facilitate the desired . id="p-15" id="p-15" id="p-15" id="p-15" id="p-15" id="p-15" id="p-15" id="p-15"
id="p-15"
[0015] In an example embodiment, the system provides a onal database system in which one or more fields of information relating to a patient, physician and drug treatment are accessed and analyzed to determine suitability of an intervention based on a relationship between any of the fields of information or combinations thereof, and a desired attribute or result, such as patient compliance, improved patient outcome or other concern. Using the fields of information and one or more algorithms, the system ines when an intervention is suitable, what type of ention is needed, and tasks an appropriate entity (e. g. a physician, t advocate, drug developer) to perform the intervention. For example, the system may determine from patient and physician data that a particular patient is unlikely to continue ent or may likely experience a sub—optimal treatment result. A suitable intervention may include outreach to a patient or physician by a pharmacy or by the drug developer to provide an indication or communication to the physician or patient of information associated with the treatment regimens or information relating to the patient so as to improve patient compliance. The intervention may be tasked by various means, such as an electronic ication or an alert through e-mail or Wireless device, to one or more entities suitable for performing the intervention. Thus, by identifying the suitability of an intervention, often before observable sub—optimal outcomes or attributes develop, and tasking an appropriate entity to perform the intervention, the system facilities the desired outcome or attribute, thereby improving patient outcomes or facilitating treatment or other related COIICGI’II.
These aspects described above can be fiirther understood by reference to Figure l, which illustrates a system in accordance with the present invention. This system includes a relational database system in which fields of information are related to one another. In certain aspects, the relationship information may access fields of information stored in different databases associated with multiple different entities such that all fields of information are not ed to be stored on a single database. This allows for improved operation of the system by reducing storage requirements and streamlining is of accessed data. This also allows the relational database to analysis c data since the information stored in the different existing information s maintained by various ent entities (e.g. hospital, physician, pharmacy, tor). In another aspect, any or all of the fields of information may be stored within a le memory within a system including the relational database. The fields of information may be stored on one or more databases and typically are input by one or more entities, for example by the drug developer, and the information is analyzed according to one or more algorithms or relationships stored in a processing unit of the . The relationships or algorithms may be ined by the sing unit in a number of ways. The onal database system described herein may utilize a database, one or more inputs by a user and one or more user display interfaces for communication an intervention or task to a user. The system may utilize a processing unit having one or more processor, a server and may include a readable memory for storing information and/or algorithms associated therewith, which may include al memory components or a cloud .
In certain es, the onships or thms may be automatically determined by the system based on statistical analysis of the information, may be input by or more es as they become known, such as determined through clinical studies, or may be automatically updated to the system from any number of sources accessed by the system In this example, the information and algorithms are input on a relational database system maintained by the drug per, although it is appreciated that the information and algorithms input into the system can be received from various different entities or ed automatically from various different databases or information sources. Once the system relates the fields of information with one another and/or to a desired attribute or result (e.g. improved patient outcome, patient compliance, reduced shipping times or reimbursement processing times), a suitable intervention is identified and tasked to the appropriate entity.
The system may determine one or more interventions based on the relationship of the information to the desired attribute/result and may task the one or more interventions to one or more es. Figure 1 rates the system tasking an intervention to each of the entities, although it is appreciated that, in many cases, a suitable intervention may be tasked to fewer than all entities or may include a particular sequence of interventions by one or more entities.
An important aspect of the system lies in the disparate data sets of information that are not accessible by any single individual or organization without such a database. The relational database has the ability to compare data fields from different incoming datasets (pharmacy data, patient advocate data, insurer information, etc.) and make an assessment about whether the data represent the same individual person. Once identified, the relational database can assign a unique identifier that connects all unique identifiers in the incoming datasets such that all future information is related to the unique individual. To provide an example of how this might be done, we may receive; shipment information that es destination zip code and patient name from a pharmacy, t name and city from the se that the Patient Advocate Program s, the name of someone commenting about their disease on Facebook and patient name and prescription dose from the hub services organization. In each of these datasets, the individual will have ent unique identifiers.
It is only the constant comparison of data that may allow the database to identify that these are in-fact the same patient by relating specific identifiers (name, location, prescription quantity, ship quantity, etc.) Without a relational database that operates on a constantly refreshing basis, the ability to tie information together would be difficult and would inhibit the ability of the system to identify risks and te actionable tasks.
Once a unique identifier is available for each patient, all data can provide a complete picture of what is happening and what interventions might be need to take place.
For example, if a patient were identified as having a denial for ge based on a new prescription, the database would have information to e nce. The database could compare this denial with patients that have the same diagnosis codes (from the pharmacy), same quantity for prescription (pharmacy), same health insurance plan (hub services provider) and identify potential reasons for the outcome. Upon comparing, the system might identify that the most likely reason for the denial is administrative error. In that case, it could task the hub services provider or local field person to speak with the office and have them review appeal documentation with the appropriate person in the ce or associated network of ting personnel to remedy the error.
In another aspect, the system allows for analysis and identification of one or more fields of information in relation to a desired attribute or result. For example, the one or more fields of ation may relate to a t, physician, pharmacy, insurance, disease state, drug or therapeutic, drug shipments, various administrative programs or processes, or any combination thereof. The system accesses the fields of information in a relational database such that one or more fields of information, or combinations thereof, can be analyzed and a onship between the information and a desired attribute or result can be identified and/or ined. Some or all of the fields of information may be stored on the database, or may remain stored on different databases, many of which are not accessible between or the types of information compatible with for comparison/analysis, outside of the system of the t invention.
The ute or result of which a user may desire to determine the likelihood of based on the information may include any of a treatment outcome, t compliance, or various attributes associated with treatments or various business or administrative concerns, such as shipping, accounting, and payment processes relating to the medication or therapeutic compound. In such embodiments, the system may provide an output of information that identifies the onships or an output according to a custom report to be used for various other purposes, for example, forecast on, budgeting, administration, or planning.
Figure 2 illustrates s different types of information that may be input into a central database, in accordance with certain embodiments of the invention, as well various ent outputs of ation that may be provided by relating the fields of information to a desired attribute or result. In this example, the different fields of information include any of pharmacy data, patient data, patient advocate m data, reimbursement data, physician interaction data and marketing data, while the information output from ing and relating the various fields of information include any of forecast on, dispense calculations, t planning tools, patient/physician dosing notification, dispense calculations, physician interaction history, and s account planning tools. id="p-23" id="p-23" id="p-23" id="p-23" id="p-23" id="p-23" id="p-23" id="p-23"
id="p-23"
[0023] Figure 3 illustrates a process flow chart within a relational database in certain embodiments of the . The system obtains data as one or more fields of information and aggregates the information by various defining factors, for example: on, name, blinded identifiers, pharmacy information, copay data, payer, and dosing. The system relates the fields of information to one or more other fields of data such that the fields of information may be searchable on various levels by one or more data factors. For example, a first field of information, such as a t identifier may be associated with at least a second field of information, such as the patient name, the treatment, the drug, the physician, the insurer, etc., thereby allowing the first field of information to be searchable by the one or more second fields of information. These fields of information, or various combinations thereof, may be associated with a desired ute or result (e.g. improved patient ance or treatment outcomes), such that ing the information on or more levels or analyzing various fields of information or combinations of fields using an algorithm of the system identifies suitability of an intervention (or alternatively a desired information output). The algorithm may include business algorithms created by a user of the system and input into the processing unit of the system or may be determined by the processing unit by applying an algorithm, such as a statistics analysis. The algorithms may relate to key trends, such as various business concerns, or may relate to an intervention by a third party, such as an alert to the drug developer to contact a physician or patient regarding ent. Once the intervention is identified, the intervention is tasked to the riate entity, which may include notifying a stakeholder of the relevant information and of the potential n.
Advantageously, by relating various types of seemingly unrelated data, the system allows for identification and analysis of s risk factors, even when the interactions between these factors may be unknown. For example, analyzing the fields of information, or various combinations thereof, in relation to a desired attribute or outcome, allows the system identify new relationships and associations between the fields of information, well before the interactions between the varies data factors are understood. Thus, the system allows for improved methods of treatment by analyzing t and/or real-time data from disparate sources to identify suitability of an intervention and tasking of the intervention to prevent undesirable outcomes. This approach may help identify and avoid undesirable trends in treatment in ntially less time than would otherwise be identified and sed, if it all, in conventional practice. 1. System Overview In an example embodiment of the invention, the methods utilize an information system storing or having access to a wide range of data associated with any or all of the patient, the physician, the pharmaceutical, and the drug ol and allows integration of the data for use in analysis in managing the treatment methods (Part A). Analysis and use of the associated data es a relationship database thm and a g function on a user interface (Part B). By use of relational algorithms, the system determines the suitability of an intervention (Part C) based on a relationship between one or fields of ation of the data and a desired result or attribute. The relational algorithms may be input by a user or uploaded automatically into the system as such relationships are determined or become known. Once the suitability and need for an intervention is determined, the system tasks an individual or entity with the invention, which typically es identifying and assigning an individual, entity, or computer to carry out the intervention (Part D). In some embodiments, the system monitors, tracks and confirms a status ofthe intervention to ensure that the intervention is carried out. Such systems may also record the response and outcome of the intervention, which may be fed back into the system to assist in determination of various aspects of subsequent interventions for that patient or various other patients. id="p-26" id="p-26" id="p-26" id="p-26" id="p-26" id="p-26" id="p-26" id="p-26"
id="p-26"
[0026] To filI‘thCI' illustrate the concepts described above, each is described in fiarther detail below with respect to an example embodiment.
II. Part A: Data structure and integration Pharmaceutical cturers have access to a wide variety of data including but not limited to pharmacy data, reimbursement patient data, data associated with patient specific interactions and ms, data associated with physician or nurse specific interactions and programs, marketing data, e interaction data, data from insurance ies, distributors and other 3rd party service providers. In certain embodiments of the invention, the fields information from the disparate sources accessed and information associated with the fields of information are stored in a database in raw form that relates to the relationship of the data element. In one aspect, the disparate sources are external to the system and/or maintained by separate entities such that the information stored thereon is largely ted e of the present system using the relational database. Data that has been provided from a pharmacy may include a d patient identifier along with information about location of the delivery, delivery transit time, the number of s, vials or other ement of product included, date of delivery, remaining refills, and many other types of data elements. In one aspect, the patient identifier is blinded so that any other information associate with the patient and his/her ent can be analyzed by the system and accessed by one or more entities external to the pharmacy and/or medical facility without comprising the patient’s right to y. In certain aspects, the system may even communication a notification within a tasked intervention to a patient or a medical facility by use of the blinded unique identifier. Other types of data stored or accessed by the system may include data input through a website, symptom ing data, website tracking data (IP address, web traffic data) or various other types of information. This data may be housed in a central database relating to the blinded patient identification code or the system may be configured to automatically access the data while stored on disparate sources and relate the data using one or more identifiers associated with the one or more fields of ation.
Alternatively, the data may be stored over multiple databases and made accessible to a processor of the system such that data can be automatically ed and analyzed by a processor of the system. Each of the data elements housed in the l database may be stored with a unique identifier that is largely unrelated to the identifiers associated with data from other sources mentioned above. For example, while some of the data noted above may be obtained by various entities (e.g. pharmacy, delivery service, physician) in conventional systems, such data is generally stored on ate s and associated with various identifies unrelated to the particular patient or treatment. The relational database es information from each of the input databases on a daily basis and es the ability to alter datasets that are sourced in the relational database in real-time. Thus, the invention may utilize this data, either input by the patient, physician, pharmaceutical manufacturer or third party or obtained through other means, by associating each data with the patient and/or treatment. 111. Part B: Relational database Once the data described above is stored on a central database or made available to a processing unit of the system, the system identifies and/or determines onships between the data for various purposes (e.g. patient treatment, business analysis, etc.) using one or more identifiers associated with the data. Utilizing specific data element requirements and/or algorithms that identify relationships between the different data elements can transform a previously unrelated set of data and content from disparate s to become a fully related set of data and content readily accessible to one or more entities. These specific element requirements (e.g. ranges of data values, thresholds, and m or minimum values) and algorithms (e.g. relationships between multiple data values, data trends over time, weighting of data) may be input into the system by a third party or may be determined by the system based on an ation of the data relationships and a desired outcome (e.g. patient, treatment or business). id="p-30" id="p-30" id="p-30" id="p-30" id="p-30" id="p-30" id="p-30" id="p-30"
id="p-30"
[0030] An e of a relationship between data ts that could be utilized in this case would be a combination of the number of days between when a patient receives shipment, the number of outreach attempts to contact the t in which the person that conducted the outreach was unable to reach the patient (left a ail rather than speaking over the phone for example), the dose of the patient and how many refills are left on the prescription. This type of patient may trend themselves out of a population of patients that are likely to achieve a successful clinical result and are therefore likely to become non- compliant. When this is identified, the system could highlight this patient as high risk and task the t Advocate Program to contact the patient more regularly and pre-schedule the activities or it may recommend that a field representative speak with the physician about the optimal method of ng patients to ensure a proper clinical result. The system may, however, take those same data ts and apply two more pieces of information (prescribing physician and diagnosis codes) and be able to identify that the patient has more mild disease and is being d in a similar manner to all other patients that the physician has prescribed the medication to. In this instance, it may weight more heavily on these data ing disease severity and physician behavior and only suggest that the pharmacist reachout and offer another consultation as the risk for discontinuation or poor efficacy may be less likely when looking at t specific information alone.
Applying these techniques allows the system to access data elements relate the elements to one another and output relationships between elements or analysis to a user or to automatically perform various functions in response to a determine relationship. With access to this system, a user has the opportunity to view data and unique reports output by the system, thereby allowing for ad—hoc analysis of the t treatment or an associated administrative s. As an example, by identifying a shipping date for a prescription refill, the system can identify the amount of copay (relate to copay transaction date), physician name (relating to patient location or other reimbursement service ers), payer name and insurance information (relating to copay transaction information), and a most recent ction between the company and the physician (relating to physician information) among many other possible combinations ofrelationships. An example custom report is shown in Figure 6C.
IV. Part C: Data Analysis/Algorithms In certain embodiments, the system applies data requirements and/or relational algorithms to the data information stored or access by the system to identify the need or suitability of an intervention. These data requirement and/or relational algorithms may be input into the system by any of the entities described herein or may be ined by the system itselfbased on data associated with results and outcomes of past interventions relating to the same or similar data. In one example, the system analyzes data relating to dosing, on a physician level, in particular the dosing ibed by a particular physician to their patients.
Data relating to these aspects are illustrated in the sample user report shown in Figures 6B.
Studies have shown that ent often vary according to the physician administering the ent, such that associating a patient and treatment with their physician, can identify a need for an ention with the physician rather than the patient to assess or modify the manner in which the physician is prescribing or administering the treatment. If the patient dosing does not progress with either: prior dosing for the physician that is deemed acceptable given clinical data supporting efficacy or dosing falls behind our clinical data when there is minimal prior physician data, the system identifies these physicians as being at risk to proper treatment. Whether treatment of a patient results in favorable outcomes often relies on whether a physician properly titrating their ts, that is prescribing a drug regimen that maintains therapeutic levels of the drug within the patient and typically adjusting or limiting the dosage or n to avoid unfavorable side effects. Advantageously, in one aspect, the system determines likely eutic levels of the drugs indirectly through various combinations of information that are accessible, without requiring test results. While the proper dosage and n may differ between patients, in some cases, a physician may not properly titrate the patients and the prescribed drug regimen may be sub-optimal such that the therapeutic effect of the prescribed drug is sub-optimal or eliminated ly. A physician may fail to properly change a t’s dosing (dose titration) for any number of reasons, ing lack of knowledge regarding the most recent clinical data associated with a given drug/treatment or a given patient population, lack of supply of the prescribed drug, and administrative or costing issues relating to the treated patient or associated health care service plan or r.
By use of the system to identify patients that were not properly ing, suitable interventions were determined and carried out resulting in an increased rate of dosing approaching that of clinical studies and decreased unenrollments and discontinuation of ents. Thus, field studies indicate that the system can identify patients that might otherwise have timal treatment early and improves patient outcomes in such cases or tinue treatment as needed. In another example, in field studies, the system identified patients that were likely to discontinue early in treatment due to expected side-effects based on a combination of attributes associated with the patient. As an example, such attributes that could correlate to a patient falling off y for ed side effects could include; a prescription n with a very high starting dose and more than 1 refill, a patient that provides information to the pharmacist or Patient Advocate that they have no scheduled appointments or upcoming laboratory draws, a t that is elderly. In each of these examples and specifically in combination, we have data that support higher likelihood of the common e events reported in clinical studies and therefore can provide preventative intervention. By determining suitability of an intervention in such cases and tasking one or more parties to outputting information in response directly to the patient and/or physician ing expected side effects, patient compliance was shown to be improved. id="p-34" id="p-34" id="p-34" id="p-34" id="p-34" id="p-34" id="p-34" id="p-34"
id="p-34"
[0034] In certain aspects, where the system identifies a consistent need for interventions, particularly where the need is associated with a particular field of information or with a ular patient population, the system can assess suitability of an intervention program, such as a patient compliance or patient advocate programs, and automatically enroll participants or output eligibility information for those patients to one or more parties. Field studies indicate that when the system revealed the suitability of such programs, enacting these programs results in a statistically significant decrease in discontinuation due to predictable side-effects. As an example, Patient Advocate Programs are in place to help patients better understand their disease, how to find correct specialists, how to deal with the challenges of treatment and identify resources (financial or ise) that may be necessary to support successful treatment of a patient. Patient te Programs often assist patients by helping them to understand the biology of their disease and how treatments can specifically alter the course of that biology. In doing so, these programs collect a great deal of ation regarding a patients education level on a disease state, the things that are of concern to them during the treatment process (cost, job stability, etc.) and their plan on working with their physician. The combination ofmany ofthese data points with data from other datasets can help identify potential risks in ways that other information sources.
While the above rate examples of fields of information used by the system to improve patient ent and patient compliance, the system may further include various other fields of ation, that may intuitively appear unrelated to patient outcomes from a treatment using a particular drug protocol. For example, the fields of information may include identification of an insurer or health care service plan or copay information. Such information may also be useful in determining suitability of interventions in various other aspects related to ent, ing strative and business processes. By relating seemingly unrelated fields of ation from different and/or disparate information sources, the system may determine a need for an intervention that might otherwise not be identified. For example, field studies indicated that various fields of information, such as geographical location, patient sub—populations or copay s, pond to a perception by ular physicians that the patient cannot afford the treatment resulting in the physician providing the patients with lower doses in the hope of saving the patient money. An example of this is comparing dose and long-term drug adherence for patients that receive drugs through a free program versus those that receive drug that is paid for by their insurance.
These data show that patients on free drug programs remain adherent to medicine longer and at higher doses at least two patient populations. In both of these ces, patients on free drug ms received higher doses of medicine than their counterparts on insurance, even when treated by the same physician. These situations lead to increased ces of non- titrating patients and sub-optimal patient outcomes. Since this relationship is particularly complex and may vary by physician, the system is advantageous in identifying the need for an intervention, as well as the most suitable type of intervention and on the level to which the intervention should be tasked. The system was able to determine an intervention for these particular physicians and task a third party, namely the drug developer, to communication with the physician the availability of financial programs to allow such patients access to proper doses at reduced costs. Timely determination and tasking of interventions by the system demonstrated an adverse selection bias in uninsured patients enrolled a free drug program. Analysis of patient compliance and t outcomes in these cases demonstrate that uninsured patients on free drug program titrate at a much faster rate that closely resembles the clinical trials, refill their shipments on a more tent basis and have comparatively longer durations on therapy at considerably higher doses than insured patient (see Table 1), thereby resulting in improved t outcomes in subjects that would have otherwise likely experienced sub-optimal results or discontinued treatment. These uninsured patients, in many cases, demonstrated the best outcomes. Although the isms by which the patients have improved t outcomes may not always be understood, the system allows for identification and determination of outcomes to improve outcomes in both uninsured and insured patients, without requiring determination of a causal effect s unknown. This aspect of the system and methods of the present ion is ularly usefiJl, especially since the health care system involves complex and unpredictable interactions between multiple factors that vary widely between patients, physician and insurers. Such complex interactions will likely continue to develop in the foreseeable future. id="p-36" id="p-36" id="p-36" id="p-36" id="p-36" id="p-36" id="p-36" id="p-36"
id="p-36"
[0036] One such relationship identified by an example embodiment of the system is illustrated in Figure 4. By relating the average dose of various patient and relating the patients to a t Assistance Program (PAP), in which uninsured patients received drugs at no cost, the system reveals the patient on a PAP take consistently higher dose of the drug, such that the treatment outcomes ofPAP patients are more in line with clinical studies. In contrast, the patients on standard treatment programs, in which insurance pays a portion of drug costs or a co-pay is required, indicate that such patients take consistently lower doses of the drug such that ent outcomes tend to fall short of the results seen in clinical studies more often than the PAP ts. This aspect is but example of the unexpected relationships and trends identified by use of a system according to the present ion. As can be appreciated, relating these fields of ation to various other fields of information (e.g. patient sub-population, physician, geographic location, pharmacy, age) may fy various other associations and suitability of interventions that might otherwise never be determined using conventional methods.
Table 1: Free Drug Treatment m (PAP) versus Standard Treatment Program PAP ts that filled Rx 100% Standard fill rate (adjusted for 100% 92% 82% 82% ily use) In certain embodiments, the system receives multiple patient treatment attributes and associates one or more treatment attributes with certain aspects of the patient’s treatment that may be used monitoring the treatment, and in improving and optimizing the treatment and patient outcomes. The patient treatment attributes includes one or more factors relating to the patient and/or the treatment, including but not limited to patient ation, ent information, geographical information, and health care services/administrative information.
Patient ation may include identifying information, demographics, geographic ation, health related information, family and/or l histories. Treatment information may include information relating to a particular treatment, drug regimen, pharmaceutical information, and information relating to drug administration, absorption and drug interactions. Health care services/administrative information may include physician information, physician treatment histories, cost information (e. g. copays, drug costs) and any ation relating to a t’s health care service plan or insurance. The system associates one or more of these patient treatment attributes with a ular type of ent and identifies the ility of an intervention based on the association of the one or more patient treatment attributes with decreased patient compliance with a course of treatment and/or sub-optimal patient outcomes. An intervention may include modifying a patient’s prescribed treatment, providing additional guidance to the patient, physician or third party relating to the treatment or stration thereof, so as to prevent d patient compliance or sub-optimal outcomes early in treatment, thereby improving patient outcomes in patients that might otherwise have been deemed unsuitable for treatment or suffered debilitating or deleterious outcomes.
In various embodiments, the system s a ity of patient treatment attributes and associates n attributes or varying combinations of attributes with decreased patient compliance or sub—optimal patient outcomes based an algorithm relating the attributes with sed patient compliance and/or patient outcomes. These associations may be determined by the system according to a termined algorithm input into the system, such as may be determined from patient s of treatments obtained over time, or the system may be configured to perform a statistical analysis utilizing patient compliance information and/or patient outcome information input directly into the system. In the former approach, the accuracy of the system in identifying the suitability can be improved over time, for example by periodically ng the pre-determined algorithm as various associations become known through medical studies, while in the latter approach the system may continually identify associations even those that may be unknown or unlikely to be ered in a formal medical studies. Various factors and combinations of factors may have complex interactions affecting the likelihood that a patient complies with a prescribed treatment or whether a physician prescribes or administers the treatment properly. For example, a geographic location of a physician may be indicative of a physician’s ance to prescribe the most current treatment regimen, while the geographic location of the patient relative the drug supplier may an sed likelihood of lapses in compliance during treatment. Even if such ation is known to a drug developer, health care administrator, or physician, these associations may not readily be evident, particularly when the association relies on a complex interaction between multiple factors. In addition, certain ations of attributes may correspond to certain other unknown or ized factors that may adversely impact a patient’s treatment such that these factors can be accounted for by the system. This aspect if particularly advantageous over conventional medical information systems and methods of ent administration. This ch is especially useful for treatments utilizing drug regimens administered over a relatively long periods of time, and in particular, treatments using drug regimens where efficacy and nce of the drug varies considerably between patients, which may result in highly variable patient outcomes and/or reduced patient compliance. These difficulties, which may be pronounced in more able patient tions, can be reduced considerably or eliminated using the system and methods of the present invention so as to provide ed patient outcomes in patient that might otherwise have discontinued ent or experience sub-optimal s.
An example of a treatment that can be lt to manage due to less table patient response is administration of a synthetic steroid, such as mifepristone. Mifepristone is a synthetic steroid that binds progesterone and glucocorticoid receptors and has been employed to treat a number of conditions including meningioma, uterin fibroids, hyperadrenocorticism, and n psychiatric illnesses. It has been surprisingly discovered that administration of the same dose ofmifepristone can produce widely varying plasma drug concentrations in different patients. For the same dose of mifepristone, the plasma drug concentration can differ by as much as 800% from one patient to another. The varied plasma drug concentration can result in some patients not receiving an efficacious dose of mifepristone. For these patients in particular, it is necessary to improve the pharmacokinetics of istone upon administration. Treatment with mifepristone can be fiarther understood by reference to the following commonly—owned application: US. Application No. ,465 filed November 15, 2012 entitled "Optimizing Mifepristone Absorption," the disclosure of which is incorporated by reference in its entirety. It is understood that the methods and systems of the present invention may be used in variety of treatments, and are ularly advantageous when used with complex and difficult to manage treatments, such as any therapy that requires dose titration over time. The length of such ies may extend over a period of weeks, months, a year or many years.
An example of this difficulty could be shown with glucocorticoid receptor nists, which involves blocking the activity of a certain type or types of hormones at a receptor level. A consequence of doing this causes an imbalance in the systems within the body. Patients will become tired, fatigued and us as their bodies have become accustomed to high doses of ds on a chronic basis. Blocking the ty of these steroids leads to a feeling of withdrawal, similar to the effects that a patient feels when trying to stop taking recreational drugs that they have become addicted to. In addition to these effects, the concentration of the hormones in the body remains very high since the activity of hormone production is not altered. This can cause additional effects on other systems that need to be monitored and controlled. A specific affect that is noted by orticoid antagonists is that the hormones that are blocked can flow to other systems within the body and create excess activity on the mineralocorticoid or (which is unblocked). This activity can cause patients to have significant swelling and reductions in potassium levels, potentially to ous levels. Without the proper use of mineralocorticoid antagonists in combination with glucocorticoid antagonists and finding a new balance with each titration, patients may never benefit from the therapy. Another example of a difficult to manage therapy is herapy, which often involves administration of chemotherapy agents in a ent regimen over three months or more and require tight adherence that may benefit from timely interventions. These are but a few examples of difficult to manage aspects of treatment that are not adequately addressed by conventional treatment methods and that may benefit from application of a treatment system and methods in ance with embodiments of the invention. id="p-41" id="p-41" id="p-41" id="p-41" id="p-41" id="p-41" id="p-41" id="p-41"
id="p-41"
[0041] In certain embodiments, the system analyzes the fields of ation using one or more algorithms input by a user. Such algorithms may incorporate relationship or ation obtained through clinical s, or may relate to various other concerns, such as business or administrative processes. An example of a specific algorithm is described as follows: a iption written at a low dose with 12 refills is interred into a t’s medical information maintained by their physician or medical facility, upon entry by the pharmacy, the system identifies that the patient does not have a physician follow-up, which triggers an intervention determination and tasking of the intervention to a Patient Advocate of an indicator to initiate contact with the patient and/or physician to obtain more information about follow-up, such as potassium and blood draws for laboratory work. The system es confirmation by the Patient Advocate of the risk necessitated intervention and tasks the Patient Advocate with another task (e.g. directed the patient to speak with the physician regarding the follow-up laboratory blood work. The system then tasks a field representative to provide information regarding the —up laboratory work to the physician. In some embodiments, the system creates a hold at the pharmacy so that the pharmacist is required to contact the physician to discuss the follow—up laboratory results and discuss any adverse events before filling a subsequent prescription, particularly when the uent prescription involves a change in dosage.
As can be tood in the above example, a particular intervention may include le aspects performed according to a particular timing and/or sequence, in order to adequately address the risk associated with the ined intervention. In this example, the first task of the intervention was to determine whether follow-up blood work was planned, the second task was to notify the patient to contact a physician or medical personnel regarding follow-up, the third task was to provide additional information ing -up to the physician by an tor sent to a field representative, and the fourth task was to obtain additional information from the physician regarding the -up laboratory work by the pharmacist, which was effected concurrent with a hold placed on the prescription refill.
In one aspect, these different tasks are effected in a particular sequence according to a particular timing, such as within 1-2 weeks, so as to adequately address the risk triggering the intervention within a suitable time frame for a given treatment (e.g. within the window of a single prescription). Advantageously, such a configuration allows the treatment to be properly titrated, while avoiding lapses in medication between prescriptions or undesirable changes in dosage. By coordinating multiple tasks output to multiple different entities, each associated with a different ation system (e.g. pharmacy, medical facility), the system allows for improved efficacy of difficult to manage treatments. As many pharmacies, physicians and medical facilities have become overburdened with management of information, such a system can become invaluable for a difficult to manage treatment, such as a treatment with glucocorticoid receptor antagonists. es of information that may be utilized within such systems include drug information relating to the drug treatment of concern. For example, studies indicate that in administration of mifepristone, plasma levels within the t drives the drug response.
This relationship is illustrated in Figure 5. By including this relationship within an algorithm of the , the system may identify fields of information, or combinations f, that pond with cient plasma levels. Such factors may relate to insufficient titration, low dosages, t attributes, age, diet, through s interactions that may be undetermined. Utilizing the system to store, relate and analyze such factors, however, allows the system to monitor various factors and intervene as needed to ensure appropriate plasma levels are maintained and facilitate zed treatment outcomes. Advantageously, the system may e these benefits even without identifying the relationship to plasma levels or that the plasma level was the factor at issue. This relationship demonstrates some of the complexities and challenges associated with a ent utilizing administration of a drug that the present invention addresses to further improve such ents, particularly in vulnerable t pulations. id="p-44" id="p-44" id="p-44" id="p-44" id="p-44" id="p-44" id="p-44" id="p-44"
id="p-44"
[0044] Patients utilizing istone to treat medical conditions require intensive follow- up to achieve optimal care and resolution of symptoms, which can lead to variable patient outcomes. Patients in which intervention may be needed to ensure optimal treatment can be difficult to identify before treatment is either discontinued by the patient or by the physician.
This difficulty is due partly due to the manner in which the pharmaceutical data, medical ation, and patient information is obtained and maintained. In conventional system, such ation is maintained by various te entities and, even when such information resides in a common repository, the data remains y unrelated. For example, although pharmaceutical manufacturers provides a substantial amount of data regarding a particular pharmaceutical, which even if provided to the patient or maintained in a system by the physician or medical provide, remains unrelated and unassociated. This may be due partly to the highly unrelated nature of most pharmaceutical manufacturer data provided.
Similarly, various other factors or combinations of factors associated with differing fields of seemingly unrelated information may have considerable effects on ent that would be difficult to predict. Regarding fields of information relating to an associated pharmacy may affect patient compliance or treatment efficacy, particularly in treatment indicating GR-II antagonists, since ent cies operate in different manners.
Another field of information that may cause an effect in some cases, either directly or indirectly is the location of delivery. For example, the system may utilize this information by mapping the location of the delivery to the location of the prescribing physician. For some patient populations, this may be used to determine the likelihood of a patient to make frequent Visits to their physician for checkups and lab work. While some physicians draw patients almost exclusively within 30 miles, other physicians, particularly those at teaching institutions, may have no patients within 500 miles. By analyzing such information, the system can ine the suitability and type of intervention on a physician level or a patient level. For example, one such intervention may be to conduct an ch to an affected patient and to ensure a local physician is available to monitor the patient’s signs, symptoms and key blood levels and offer patient support. In some ments, the system may provide an automated intervention to such patients and recommend ians that may be closer to them geographically to monitor basics in—between visits to their primary prescriber or recommend an appropriate outreach program In various embodiments, the system may utilize any number of algorithms to determine statistical relevance of one or more fields or combinations of fields to a result, the result being associated with one or more of patient compliance, patient es, treatment or various business related aspects. By applying statistical analysis, the system can ine the likelihood that a result or relationship is caused by something other than mere random chance so as to determine if the field of information or combination of fields is statistically significant to the desired result. The analysis provides a "p-value" representing the probability that random chance could explain the . In general, a 5% or lower p-value is considered to be statistically significant, although the threshold of significance and desired confidence level may be selected or varied as desired to facilitate a desired result or fy information or relationship relating to a d attribute or business concern.
In certain embodiments, the system may e an algorithm that apply a known or predicted ation between one or more fields and a result that is input by a user or included in a system update. Such algorithms may be determined ically as ations are identified through clinical studies or otherwise. In some embodiments, the system may apply statistical analysis to determine associations between one or more fields and a result in addition to ng an algorithm input into the system such that the statistical analysis of various fields of information can be reassessed as s other associations are fied over time. These features provide further improvements as ever more complex interactions between the fields of information can be identified and interventions tasked to inhibit or reduce adverse s associated with such interactions.
V. Part D: Identifying and assigning human or computer intervention Once the need or suitability of an intervention is identified by the system, the system may select a particular type of intervention based on data relating to the patient and/or treatment, which may include any of the attributes or data factors described herein. The data information stored and/or access by the system is used to select or determine the most effective form of intervention for a given condition. This selection of intervention type may be based on a data requirement or algorithm input by the user or may be determined by the system based a relationship between one or more of the data factors and success of past interventions associated with the same or similar data factors. In addition, this selection/determination of intervention type may utilize an algorithm so as to determine the most suitable type or form of intervention based on a x relationship between multiple data factors.
By identifying the need for an intervention and providing a timely intervention, patient compliance can be ed and/or treatment can be optimized to improve patient outcomes. In addition to determining the suitability of an ention based on the data and/or data relationships, the system identifies an appropriate party to perform the intervention and tasks the identified party to perform the invention. The intervention may include a communication by phone, e—mail, or any suitable means to any entity associated with the treatment and/or patient (e.g. a physician, health care administrator, pharmacy, patient or ker, or third party). The ention may be performed by any of the above entities or by an automated unit of the system (e.g. automated text, voicemail, or e-mail reminders or alerts). In addition, the system may track the status of the intervention, monitor the result of the intervention and/or follow—up on the status of the intervention to ensure it was performed timely. Timely intervention based on these data will help to improve patient care. The methods and system of the present ion are ularly useful in providing optimal care for patients undergoing a treatment ing a drug regimen, such as mifepristone, that requires intense ian and patient follow-up due to the nature of the medicine.
Various types of interventions have been identified to serve a variety of needs. For example, an intervention may relate to delays in processing or delivering shipments of a drug to a medical facility or to a patient such that a drug manufacturer or developer may be tasked to initiate an ention to the drug supplier/delivery facility to ensure timely drug shipments. This aspect optimizes not only the business transactions between these entities, but may e patient compliance and treatment through timely and consistent drug delivery. In various embodiments, the need of an intervention is determined by the system using a relational database system t ing the fields of ation actually be stored on the system. With the combination of the relational database system and the data requirements and/or algorithm associated with a particular entity, the need for an intervention can be timely identified, specific interventions can be created and tasked or assigned to an riate entity and followed to tion. If the tasked intervention is not timely completed or the data obtained after the intervention is indicative of intervention failure, this may trigger another intervention, which may relate to the original entional condition, or to the tasking and intervention process itself. For example, if the intervention proves unsuccessful or is not timely performed by a first party tasked with the intervention, the system may indicate an ative intervention to address the original intervention condition or may task an ention to a second party to perform the intervention and/or remedy the failure of prior tasked intervention. Thus, in some embodiments, the system determines multiple tasks to differing multiple entities according to a particular sequence and timing so as to ensure a risk associated with a determined intervention is adequately addressed.
In certain aspects, tasking is performed through email but can be modified and automated in various ways if desired. Tasking may include any identifier of a task (e.g. indicator light, e—mail, text). For example, should the system determine that a ian does not regularly titrate patients, the system identifies a need for ention(s) on a physician level and task the intervention to address the problem. Such tasking may include an ted task performed by the system, such as e—mailing the primary t for the physician to check a report highlighting the physician’s challenges with proper titration and/or sending an e-mail with the report to a sales person instructing the sales person to make an appointment with the physician to discuss dosing and titration. As discussed above, plasma level se of an administered drug correlates with dosing, which may vary considerably between drugs. Although plasma level response in response to dosing may vary between patients and various factors, improving proper dosing and titration generally results in improved patient outcomes more in line with clinical s. Thus, by determining the need for and tasking entions on a physician level that relate to closing and titrating, the system allows for improve plasma level response in treated patients, in turn, ing patient outcomes. The system further improves the above noted correlations as additional factors that may relate to variations in plasma level response (e.g. sub-populations of patients, treated condition) may be identified and the interventions adapted accordingly. Completion of these tasks may be recorded by or input into the system as another field of information and associated the physician ation within the system.
In some ments, the system is configured to identify le patients for a particular treatment through various resources, such as online questionnaire or patient advocate programs provided by a developer of the treatment, and determine whether the patient’s physician had previously received information regarding the treatment. The system may identify when such a patient has an upcoming tment as a situation in need of an intervention and task a field personnel to t physician outreach to educate the physician on the treatment prior to the t visit. When used in this manner, results indicated that the identified patients were more likely to be enrolled in the treatment by their physician than in patients where no intervention occurred.
The above aspects are further illustrated by the following e embodiments of the ion. According to one example, if a ian has not increased the dose of a patient’s medication to a level that will likely generate a eutic effect, such as may be determined from patient studies or from patient monitoring data ed by the system, the system identifies that an intervention is needed to adjust treatment. The system then proceeds to select/determine the appropriate intervention(s) and task the determined ention(s) to the appropriate party or parties. As can be understood by the xities of the relationships between various data factors, a given interventional may e multiple tasks by one or more parties or entities. Examples of these tasks might include: tasking a third party pharmacist to reach out to the physician and patient to discuss potential changes to their prescriptions, tasking a manufacturer representative to contact the physician to set up educational information, tasking a patient specific program to call the patient to discuss the drug (e.g. istone), tasking a system to generate an email or fax to the office or prescriber requesting an updated prescription, or various other tasks. By use of this system according to the s described herein, the information is utilized to ensure optimal care of patient undergoing ent, particular ent involving a drug regimen requiring careful monitoring and administration, such as mifepristone.
VI. Application By ing one or more fields of information from various s and relating the one or more fields to indicators of success or failure in patient compliance and/or treatment efficacy, the system allows for identification of a need for an intervention from seemingly unrelated fields of information. Moreover, these fields of data can be analyzed on various different levels and, in turn, the resulting interventional alerts may be output on various different levels. For example, one or more fields of ation may be analyzed in relating one or more other fields of information and assessed in terms of t compliance and/or treatment efficacy. For example, a patient dosage field may be related to a physician last name field and these combinations associated with patient compliance and/or treatment efficacy. Associating these data relationships may reveal that a particular physician is not properly titrating (e.g. not sufficiently monitoring and adjusting dosages according to each patient). By analyzing these relationships on a physician level, the system can determine a need for an intervention on a physician level (e.g. an alert to a physician or to a third party to communicate with the physician) to address and remedy the physician is not a significant factor in non-titrating patient, which may indicate that various other factors or fields of information, may require analysis to determine whether an intervention is suitable. For example, patients in a remote geographical location or patients having higher co-pays may not be properly adhering to an prescribed dosage such that the system may determine a need for an intervention on a patient level or on an insurer level. Alternatively, a determination of a reduced patient compliance or ent efficacy on one or more levels may trigger an intervention on one or more of the same or different levels. In certain aspects, the result of an intervention alert is received as yet r field of information, such that the determination of an intervention and the type and level of intervention determined can be analyzed and further optimized based on success or failure of past interventions.
To r illustrate these concepts, use of the system is described in regard to a determined relationship between dosage and shipment data analyzed on a physician level.
When the drug is supplied to the t directly by the drug developer or manufacturer, the system can e shipment data to determine an actual dose received by the patient, even when the actual dose ed by the patient differs from the prescribed dosage. For example, if a nt includes a 30-day drug supply at 300 mg/day, the nt data can be ed to ine a patient’s treatment dosage, as well as changes in the dosage over time. Typically, one shipment includes a 20-day supply with most ts taking one to four tablets each day (300 mg — 1200 mg). By associating the dosage data with the patient’s physician, analysis and intervention is performed on a physician level, as shown in Figure 6B, allowing the system to identify physicians whose dosing falls below therapeutic levels as determined by clinical data. The system then uses this information to identify where an intervention is needed, select or determine appropriate intervention(s) and task the appropriate party or entity to perform the intervention. In ining the suitability of an intervention on a ian level, the system may further include various other factors relating to the physician, such as the level of experience of the physician, physician history, and geographic information. These factors can be used to ine whether an intervention is needed, as well as what type or form of intervention is most appropriate. For example, each physician may be rated as "experienced" or "not ence" or ranked on a scale based on their previous experience with a particular drug treatment and whether the physician has a history of successfully treating patients with the drug. If a ian is enced with a particular drug treatment, the system may apply higher triggering thresholds for indicating an intervention condition. If the physician is less experienced, the physician may be less likely to titrate patients properly, which may lead to lower efficacy, shorter duration on therapy and decreased t compliance. When the physician is less experienced, the system may use a lower threshold to trigger for indicating an intervention condition and may determine different types and forms of interventions than would be indicated with an experience physician. When the physician is less experienced or when there is cient physician information, the system may analyze additional factors when determining whether an ention condition is present. For e, such as monitoring of prescription data information (e.g. number of refills at non—titrating doses). The number and type of interventions determined may also differ according to the ence of the physician. For example, when the physician is more experienced, an onic communication (e. g. e-mail, text), may be te, while when the physician is less enced, the system may output an alert to field personnel to initiate closer contact with the physician and/or patient by phone or in person to discuss ent and possible side effects. Such interventions may be necessary in these circumstances, since such physicians may be more likely to overreacts to any adverse events or ffects experienced by the patient and potentially discontinue the therapy before efficacy can be realized. In addition, the intervention may include contact and communication directly with the patient by any of a patient advocate, nurse, pharmacist, administrator, and reimbursement service provided so as to educate the patient or address potential concerns thereby improving likelihood of patient compliance and successful outcomes of treatment.
As can be understood by the examples above, the data ements and algorithms that trigger a determination of an ention condition can be quite simple or fairly complex. For example, multiple shipments of low doses or single nts at very low doses can trigger an intervention to t the prescribing physician and request more information regarding the treatment or to educate the physician on recommended dosages.
The system may also be configured to perform a considerably more x analysis of factors, such as tracking the shipments to various patients over time, determining likely doses by the patient and analyzing which patients fall above or behind the titration curve of the general population based on results from clinical studies and/or the curve of a specific physician. Such analyses allows the system to identify patients that may be outliers early in treatment and through the intervention and tasking ses described above, provide additional ring and attention to those patients that might otherwise experience sub- optimal outcomes. In another aspect, the system may associate various other fields of patient information, including aphic information, health information and disease state or severity, such that the system can identify ial sub-populations requiring interventions to improve patient outcomes In certain aspects, the system is configured with a user interface that displays the information output of one or more fields of information in response to a request or search entered by a user. One such example is illustrated in Figure 6A, which lists a weekly report of indication data, and a detail for patients being treating for Cushing’s syndrome and a weekly report for discontinued/unenrolled patients. Such reports may be ted or may be customized by a user as desired. These information outputs may be used by the system in identifying an intervention, determining a le type of intervention or tasking the intervention and may assist the user for various other es or ss concerns, such as budgeting, forecasting and planning.
In the example rated in Figure 6B, physician Smith’s patient is receiving improperly prescribed 50% of the recommended dose, while Johnson and Williams appear to have discontinued treatment after only two months. Upon identifying the physicians at risk for administering sub-optimal treatments as a condition suitable for an intervention, the system determines an appropriate intervention and tasks the appropriate party/entity. For example, the system may output an alert to the drug developer/manufacturer to ication with physician Smith and provide information or counsel to physician Smith as to the recommended s or the intervention may be automated such that the system automatically send an electronic communication (e.g. text or e-mail) to physician Smith or associated staff personnel that the prescribed dose is likely to fall below therapeutic levels or that the patient is ng ordering refills and is likely not taking the drug at the prescribed dose. The system may utilize the same or similar interventions to communicate to physicians Johnson and Williams that two months is insufficient duration to assess suitability or efficacy of the drug treatment or lack of compliance by the patient. In response, the system determines whether an intervention is required, and tasks the intervention h one or more tasks that are tasked to one or more different entities according to a particular sequence and timing so as to improve ent efficacy and patient compliance by avoiding undesirable lapses in medication or changes in dosage that may adversely affect treatment. id="p-59" id="p-59" id="p-59" id="p-59" id="p-59" id="p-59" id="p-59" id="p-59"
id="p-59"
[0059] An example information output report provided by the system is shown in .
Such information may be returned in response to a request or search by a user, or may be automatically provided within a tasked intervention to provide the tasked entity with relevant information to tand and perform the tasked intervention. For example, in response to received data ting that a dosage of 300 mg/day is needed for a duration of at least four months to ensure that the patient receives eutic levels of the drug in order to assess the efficacy of the treatment, the system may analyze the stored and related fields of information and identify the need for an intervention on a physician level and output the relevant information within a tasked ention as to which physicians are failing to properly titrate their patients. atively, if analysis of the fields of information indicates lapses or delays in ordering refills that may be indicative ofreduced patient compliance, a tasked intervention may include contact with the patient, enrollment in a Patient Advocate Program or interfacing with the insurer to s administrative or cost concerns.
In an example embodiment, the system may monitor and track the number of shipments of a particular drug to a physician over time and associate this shipment information with the number of patients treated with the drug by the physician to ine whether the physician is properly titrating their patients, without ever directly receiving prescription ation from the physician. In another aspect, if the shipments are shipped directly to the patients, the system can determine which physician require an intervention by determining a patient’s dosage based on the number of shipments over time and associating this data with their physician. t studies indicate that dosing has a significant correlation in clinical trial response and that dosing correlates with plasma level response for various conditions, in ular treatment ofpsychotic depression. Current s further indicate that ts that receive four shipments exhibit substantially higher t compliance during treatment, take higher doses, and exhibit results in line with clinical studies and indicate improved outcomes based on subjective third party discussions.
In another , the system provides access to the field(s) of information such that the fields can be viewed and sorted according to one or more fields or combinations of fields or on or more levels (e.g. ian, patient, insurer, type of treatment). This e allows a user to , organize and analyze information for various purposes. Such features can be particularly useful for administrative and business purposes, such as development of free drug programs and patient advocate programs to planning and shipments of drug manufacturing and shipping. The system may be configured with a user interface that allows a user to create a custom report that may be used for various es. For example, the custom reports may be used to identify optimal data requirements or relational algorithms that may be of use in further clinical studies or may be of interest to s entities utilizing the system. In addition, the custom reports may be useful for analysis any factor relating to treatment or to analyses various other factors, including transaction, administrative and ss processes.
Example methods in accordance with the present invention are illustrated in Figures 7-8. In the example embodiment of Figure 7, the method includes a user inputting a plurality of fields of information into a , including but not limited to information relating to the patient, physician, drug, drug treatment, insurer or various shipping or administrative process.
The plurality of fields of information are then stored by the system, such that the fields of information are centrally stored or are otherwise centrally accessible, and relates the fields with one another such that the fields of information can be analyzed to identify suitable interventions using a processing unit of the system. A user then determines a first field (e.g. patient info) based on a relationship between at least a second field (e. g. physician and/or drug) associated with the first field and a ular attribute or outcome (e.g. treatment outcome) using a processor of the system and one or more algorithms of the system. The user then receives an information output from the system with one or more fields of information, which may be in the form of a tasked intervention, a forecast, a notification, report or history. It is understood that this method may include any of the variations and features described in any of the embodiments described herein.
In the example embodiment of Figure 8, the system receives one or more fields of information ng to a t, physician, pharmacy, insurance or health care administration; the system then relates the one or more fields of ation allowing is on or more levels. The system then determines an intervention based on a relationship n the one or more fields of information and a desired attribute or outcome associated with patient compliance, ent outcome or a business or administrative aspect.
The system then tasks the intervention to an appropriate , as ined by the system, to facilitate the desired attribute or output information relating to a desired attribute. ally, the system may be configured to track the tasked intervention and/or the outcome of the tasked ention to ensure the intervention is performed and, optionally, the outcome of the intervention may be fed back into the onal database as an additional field of information so as to inform and improve treatment.
In the example embodiment of Figure 9, the system performs a method that includes steps of: accessing a plurality of fields of information relating to a t or treatment from a plurality of different information systems (e.g. pharmacy, medical facility, insurer information systems); ng the fields of information using a onal database of the system and determining an intervention based on the relationships of the fields of information; determining a plurality of tasks associated with the intervention with the system and performing and/or tasking the ity of tasks to multiple different entities according to a particular sequence and/or timing; and outputting a communication regarding performance of a second task based on ation received regarding a first task of the plurality.
In the example embodiment of Figure 10, the system performs a method including steps of: accessing a field of information relating to ent stored in a pharmacy information system and accessing a field of information relating to a patient schedule in a medical facility information system; determining an intervention is needed based on the prescription dosage (e. g. low dosage) and/or the patient schedule (e. g. lack of follow-up) and determining a ity of tasks in response to the determined ention; tasking the ity of tasks to multiple different entities according to a particular sequence and/or timing; outputting a communication initiating performance of a second task of the plurality (e. g. communication to field representative to educate physician) after receiving information ing performance of a first task of the plurality (e.g. confirmation from Patient Advocate tasked to inquire as to lack of follow—up); and placing a hold on the iption and communicating the hold to the pharmacy information system to be maintained until receiving information]confirmation regarding performance of a task of the plurality.
In the example embodiment of Figure 11, the system performs a method including steps of: accessing a field of information regarding a change in dosage indicated in the pharmacy information system; determining an intervention needed to determine relevant follow-up lab results and/or y as to adverse events by patient and determining a first and second task associated with the intervention; performing and/or tasking the first and second tasks, wherein the first task comprises placing a hold on the prescription and the second task comprises a request for information regarding follow-up and/or inquiry as to adverse events; outputting a communication to the pharmacy information system regarding the hold placed on the prescription and ting a communication to the pharmacist to e as to follow-up lab results and/or adverse events; and maintaining the hold on the prescription by the system until information is received indicating satisfactory -up laboratory results and/or inquiry as to adverse events by patient.
While the examples bed above are illustrative of some of the basic concepts described herein, it is appreciated that these advantages extend to risk s and interactions between risk factors that are far more complex, which conventional treatment s fail to recognize or address and might ise t a number of patients from receiving optimal treatment. The above described embodiments have been described in some detail for clarity of understanding and by way of example, a y of adaptations, modifications, and changes will be obvious to those of skill in the art. Hence, the scope of the present ion is limited solely by the appended claims.
I/
Claims (9)
1. A system for assigning a task to an appropriate , the appropriate entity being a physician, patient te, pharmacist, or drug developer involved in managing a drug treatment utilizing administration of a drug comprising mifepristone to a Cushing’s syndrome patient, the system comprising: a relational se configuration that stores a relationship between differing fields of information stored on multiple differing information systems accessed by the system, the one or more fields of information including any of a patient identifier, patient characteristic, a treatment n, drug dose information, drug refill history, symptom reporting, patient or physician ication, or any combination thereof; one or more servers on which the relational database resides; wherein the system further ses a processing unit having instructions recorded on a memory, the instructions configured to: access and relate any of the one or more fields of information or any combination thereof to a desired result; identifying, with the system and without requiring test results, patients not receiving a proper change in mifepristone dose, by A) ation of high starting dose with multiple refills, no upcoming laboratory draws, and patient is elderly, and B) combination of low starting dose with le refills, and no led appointments; determine a plurality of tasks for addressing an intervention based on the relationship between the one or more of the fields of information and a desired result, wherein an intervention is a) a modification of a patient's prescribed treatment, or b) providing guidance to the patient, physician, pharmacist, or drug developer relating to said treatment; said plurality of tasks ts of outreach to a patient or physician by a drug developer, outreach by a patient advocate to obtain information about potassium and blood draws for laboratory work, outreach by a patient advocate to notify the patient to speak with the physician, outreach by pharmacist to reach out to the physician and patient to discuss ial prescription changes, ch by a system to generate an email or fax to the prescriber requesting an updated iption; and by outputting an intervention alert to one or more electronic devices to alert said physician, t advocate, pharmacist, or drug developer and to facilitate the desired result, P232053NZ Amended Claims Marked Up (Feb 2021):26900405_1 wherein the desired result ses a proper change in the patient’s istone dose, improving likelihood of patient compliance, or a successful treatment outcome, whereby the task of performing the intervention is assigned to the ian, patient advocate, or drug developer, wherein the processing unit is further configured to select one or more types of interventions and select the one or more electronic devices to which the intervention alert is to be outputted from a plurality of electronic devices based on the determined intervention type, wherein the processing unit is further configured to monitor, track and confirm a status of the intervention to ensure that the intervention is carried out by placing a hold on a prescription and communicating the hold to a cy information system to be maintained until receiving confirmation that the intervention is carried out.
2. The system of claim 1 further comprising: a user interface communicatively coupled with the processing unit and the database configuration, the user interface configured to tate input of fields of information and/or an output of the intervention alert.
3. The system of claim 1 wherein the processing unit is configured to determine the relationship between the one or more fields of information or any combination thereof and the desired result by relating the fields of ation with a received result.
4. The system of claim 1 wherein the processing unit is configured to relate the one or more fields of information or any combination thereof with the desired result by applying a relational algorithm input into the system.
5. The system of claim 1 wherein the one or more electronic devices comprise any of a er, a personal electronic device, a smartphone, a visual or audio indicator.
6. The system of claim 1 wherein the intervention alert ses any of an e-mail, a text, audio or visual indicator, or any combination thereof.
7. The system of claim 1 wherein the processing unit is ured to dynamically update the one or more fields of information and/or the relational database relating the fields of information.
8. The system of claim 1 n the sing unit is configured to record the response and outcome of the intervention. P232053NZ Amended Claims Marked Up (Feb 2021):26900405_1
9. The system of claim 8 wherein the processing unit is configured to feed back the se and outcome back into the system to assist in determination of various aspects of subsequent interventions for the Cushing’s syndrome patient. t Therapeutics, Inc. By the Attorneys for the Applicant SPRUSON & FERGUSON Per: P232053NZ Amended Claims Marked Up (Feb 2021):26900405
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361880785P | 2013-09-20 | 2013-09-20 | |
US61/880,785 | 2013-09-20 | ||
PCT/US2014/056830 WO2015042544A1 (en) | 2013-09-20 | 2014-09-22 | Systems and methods of treatment using intervention and tasking determination |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ719045A NZ719045A (en) | 2021-03-26 |
NZ719045B2 true NZ719045B2 (en) | 2021-06-29 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020202441B2 (en) | Systems and methods of treatment using intervention and tasking determination | |
US11699506B2 (en) | Method for distribution of a drug | |
US7734483B1 (en) | Computer implemented method and system for analyzing pharmaceutical benefit plans and for providing member specific advice, optionally including lower cost pharmaceutical alternatives | |
US20080183500A1 (en) | Systems and processes for health management | |
US20110246220A1 (en) | Web Based Care Team Portal | |
US20060271405A1 (en) | Pharmaceutical care of patients and documentation system therefor | |
US20050228593A1 (en) | Method, system, and computer program for providing and evaluating medicine information | |
US20120179481A1 (en) | Recommending Prescription Information | |
US20160042148A1 (en) | Therapeutic Equivalent and Healthy Alternative Recommendation System | |
Stenner et al. | Impact of generic substitution decision support on electronic prescribing behavior | |
Monsen et al. | The effect of medication cost transparency alerts on prescriber behavior | |
US20140052476A1 (en) | Points-Based Reward Program For Improving Medication Adherence and Outcomes | |
Zivin et al. | Implementing electronic health record default settings to reduce opioid overprescribing: a pilot study | |
US20160292385A1 (en) | Systems and methods for medication dosage range determination and verification based on patient test results | |
US20150161353A1 (en) | Methods and apparatus for improving healthcare | |
US20160055300A1 (en) | Healthcare informatics systems and methods | |
Duarte-García et al. | Association between payments by pharmaceutical manufacturers and prescribing behavior in rheumatology | |
Bucher et al. | Surveillance of physicians causing potential drug-drug interactions in ambulatory care: a pilot study in Switzerland | |
Price et al. | Historical cohort study examining comparative effectiveness of albuterol inhalers with and without integrated dose counter for patients with asthma or chronic obstructive pulmonary disease | |
Gipson et al. | Optimizing prescribing practices of high-cost medications with computerized alerts in the inpatient setting | |
NZ719045B2 (en) | Systems and methods of treatment using intervention and tasking determination | |
Sandhu et al. | The impact of clinical pharmacist integration in a community rheumatology clinic | |
US20230197222A1 (en) | Systems and methods for changing a prescribed medication for a patient | |
Placzek et al. | Prior authorization in the treatment of patients with pDPN and FM | |
US20150161352A1 (en) | Methods and apparatus for improving healthcare |